Indolent Non-Hodgkin Lymphoma — Trials

Indolent Non-Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 212
Recruiting: 104
Ph III recruiting: 4
Growth YoY: +51.7%
Industry share: 20%
Top sponsor: City of Hope Medical Center
Termination share: 36.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (150)

clinicaltrialsPublishedShowing 51–52 of 52 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00101244	SB-715992 in Treating Patients With Metastatic or Unresectable Solid Tumors or Hodgkin's or Non-Hodgkin's Lymphoma	terminated	Phase 1	31	National Cancer Institute (NCI)NIH	1	Jan 14, 2013	clinicaltrials
NCT01116154	Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma	terminated	Phase 1	30	City of Hope Medical CenterOTHER	1	Dec 9, 2010	clinicaltrials